Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.
Watch this video to learn more:
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.